Reimagining Medicine Q2 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Cardiovascular
Immunology
Ophthalmology
aflibercept - VEGF inhibitor
NCT04864834 Mylight (CSOK583A12301)
Ophthalmology indication (as originator)
Phase 3
Indication
Phase
Patients
460
Primary
Outcome
Conclusions
Neuroscience
Global Health
Measures
Arms
Intervention
Best-corrected visual acuity (BCVA) will be assessed using the ETDRS testing
charts at an initial distance of 4 meters. The change from baseline in BCVA in
letters is defined as difference between BCVA score between week 8 and
baseline
Arm 1 Biological: SOK583A1 (40 mg/mL)
Arm 2 Biological: Eylea EU (40 mg/mL)
Patients with neovascular age-related macular degeneration
Target
Patients
Readout
2023
Milestone(s)
Publication
tbd
Appendix
References
Innovation: Clinical trials
Abbreviations
Oncology
Other
Biosimilars
88 Investor Relations | Q2 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation